Eli Lilly (LLY) Cash & Equivalents (2009 - 2026)

Eli Lilly has reported Cash & Equivalents for 18 years, with the latest figure at $5.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 70.76% year-over-year to $5.3 billion; the trailing twelve-month figure through Mar 2026 stood at $5.3 billion (up 70.76% YoY), and the FY2025 full-year result was $7.3 billion, up 122.4% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $5.3 billion, down from $7.3 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $9.8 billion in Q3 2025, with the low at $2.1 billion in Q4 2022.
• Historically, Cash & Equivalents has averaged $3.7 billion across 5 years, with a median of $3.1 billion in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 45.87% — and 2025, when it jumped 190.65%.
• Eli Lilly's Cash & Equivalents stood at $2.1 billion in 2022, then surged by 36.36% to $2.8 billion in 2023, then increased by 15.94% to $3.3 billion in 2024, then soared by 122.4% to $7.3 billion in 2025, then retreated by 27.33% to $5.3 billion in 2026.
• The last three Cash & Equivalents figures came in at $5.3 billion (Q1 2026), $7.3 billion (Q4 2025), and $9.8 billion (Q3 2025), per Business Quant data.